睿知中国医院研究地图
候选清单

正在招募乳腺癌I/II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

GQ1001 Combined With Pyrotinib for Treatment With HER2 Positive Metastatic Breast Cancer

ClinicalTrials.gov 上登记的一项乳腺癌开放试验,由复旦大学附属肿瘤医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方(推断)复旦大学附属肿瘤医院Fudan University Shanghai Cancer Center上海医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT05575804,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 9

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(9 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Histopathological and/or cytological confirmed Her2-positive locally advanced or metastatic breast cancer (IHC3+, or IHC2+ and ISH+), *ISH: Fluorescence in situ hybridization (FISH) or dual in situ hybridization (DISH); ISH positivity is defined as a ratio of HER2 gene copy number to CEP17 signal number ≥2.0. When the immunohistochemical (IHC) result is 3+, ISH testing is not required. When the IHC result is 2+, ISH testing should be performed to confirm HER2 positivity.

    入选标准第 5 条

  3. Potent CYP3A4 inhibitor≥3*t1/2 weeks;

    入选标准第 31 条

    Participants who have received pirlotinib treatment during the recurrent and metastatic stage, discontinued the medication due to reasons other than disease progression, and have progressed more than 6 months after discontinuation are allowed to be enrolled;

    排除标准第 4 条

    Participants who have received treatment with ADC drugs with different small molecule toxins (such as DS-8201, GQ1005, SHR-A1811, etc.) are eligible for enrollment. Such patients are also allowed to have received pirlotinib treatment during the recurrent or metastatic stage, and those who have progressed after more than 6 months of pirlotinib treatment are also eligible for enrollment.

    排除标准第 5 条

  4. Failure for at least 1 line of standard systemic treatment for metastatic disease. Meet one of the following conditions:

    入选标准第 6 条

    Recurrent within 12 months after completing or during neoadjuvant/ adjuvant therapy (the regimens contain trastuzumab or its biosimilar with pertuzumab or not).

    入选标准第 7 条

    Clinical symptomatic brain metastasis is defined as untreated and symptomatic, or requiring steroid or anticonvulsant treatment to control related symptoms. Patients with asymptomatic brain metastasis, or with stable clinical symptoms and no need for steroid hormone and other treatments for brain metastasis for ≥28 days, can be enrolled.

    排除标准第 1 条

    Have previously been treated with: another antibody-drug conjugate (ADC) consisting of DM1 or its derivative,pyrotinib and capecitabine,except for the following situations:

    排除标准第 2 条

    During (neo)adjuvant therapy, received pyrotinib, and the participants who have experienced recurrence or metastasis more than 6 months after the last treatment and have not received pirlotinib since then are allowed to be enrolled;

    排除标准第 3 条

    Having a history of myocardial infarction or unstable angina pectoris within 6 months prior to the initial treatment,

    排除标准第 9 条

    Lactating women or women who have confirmed pregnancy through a pregnancy test within 7 days prior to their first treatment.

    排除标准第 18 条

  5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1,life expectancy greater than 3 months.

    入选标准第 3 条

  6. Hematology: WBC≥3.0×109/L;NE≥1.5×109/L;Hb≥90 g/L;Plt≥100×109/L;

    入选标准第 12 条

    Liver function: Total bilirubin ≤ 1.5 x the upper limit of normal; AST and ALT ≤ 2.5 x the upper limit of normal, ≤ 5.0 x the upper limit of normal in the presence of liver metastases;

    入选标准第 13 条

    Kidney function: Serum creatinine ≤1.5 x the upper limit of normal;

    入选标准第 14 条

  7. Having at least one measurable lesion according to RECIST 1.1.

    入选标准第 9 条

  8. Have other malignant tumors within 5 years before signing the informed consent form ( except for cured skin basal cell carcinoma and cervical carcinoma in situ).

    排除标准第 6 条

  9. Female subjects who are capable of bearing children must have negative urine or serum pregnancy test results within 7 days before randomization, and must commit to using contraception throughout the study period and continue to do so for 7 months after the study ends.

    入选标准第 33 条

    Male or female subjects unwilling to use approved contraceptive methods (e.g. birth control pills, barrier device, intrauterine device, abstinence) during the study and for 7 months following the last dose of the study drug infusion.

    排除标准第 19 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT05575804,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Having provided written informed consent, and be able to follow clinical trial protocol.
  2. Men or women aged 18-75.
  3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1,life expectancy greater than 3 months.
  4. Left ventricular ejection fraction (LVEF) ≥50%.
  5. Histopathological and/or cytological confirmed Her2-positive locally advanced or metastatic breast cancer (IHC3+, or IHC2+ and ISH+), *ISH: Fluorescence in situ hybridization (FISH) or dual in situ hybridization (DISH); ISH positivity is defined as a ratio of HER2 gene copy number to CEP17 signal number ≥2.0. When the immunohistochemical (IHC) result is 3+, ISH testing is not required. When the IHC result is 2+, ISH testing should be performed to confirm HER2 positivity.
  6. Failure for at least 1 line of standard systemic treatment for metastatic disease. Meet one of the following conditions:
  7. Recurrent within 12 months after completing or during neoadjuvant/ adjuvant therapy (the regimens contain trastuzumab or its biosimilar with pertuzumab or not).
  8. Received at least one treatment with trastuzumab or its biosimilar ±pertuzumab (monotherapy or in combination with other drugs) for recurrent or metastatic disease.
  9. Having at least one measurable lesion according to RECIST 1.1.
  10. Previous exposure to taxanes.
  11. During the screening period and the first 7 days before treatment, the following indicators confirm appropriate organ functions:
  12. Hematology: WBC≥3.0×109/L;NE≥1.5×109/L;Hb≥90 g/L;Plt≥100×109/L;
  13. Liver function: Total bilirubin ≤ 1.5 x the upper limit of normal; AST and ALT ≤ 2.5 x the upper limit of normal, ≤ 5.0 x the upper limit of normal in the presence of liver metastases;
  14. Kidney function: Serum creatinine ≤1.5 x the upper limit of normal;
  15. Coagulation function: prothrombin time and activated partial thromboplastin time ≤1.5 x the upper limit of normal.
  16. Adequate wash-out periods:
  17. Major surgery ≥4 weeks;
  18. Radiotherapy ≥4 weeks (Palliative stereotactic radiotherapy without abdominal involvement radiotherapy: ≥2 weeks);
  19. Autologous transplantation: ≥3 months
  20. targeted therapy or chemotherapy≥4 weeks;
  21. Radioactive particle therapy: ≥3 months
  22. Nuclide therapy: ≥3 months
  23. Hormone therapy: ≥2 weeks, or based on judgement on the breast cancer
  24. Participants from the investigators' judgment;
  25. Endocrine therapy: ≥4weeks;
  26. Chemotherapy or targeted therapy: 5-fluorouracil-based preparations, folinic acid preparations, and/or Weekly paclitaxel: ≥2 weeks;
  27. Tyrosine kinase inhibitor: ≥2 weeks (or 5 half-lives)
  28. In the case of a decline period, the longer one shall prevail;
  29. Nitrosoureas or mitomycin C: ≥6 weeks
  30. Immunotherapy ≥4 weeks;
  31. Potent CYP3A4 inhibitor≥3*t1/2 weeks;
  32. Any investigational agents≥4 weeks.
  33. Female subjects who are capable of bearing children must have negative urine or serum pregnancy test results within 7 days before randomization, and must commit to using contraception throughout the study period and continue to do so for 7 months after the study ends.

排除标准:Exclusion Criteria:

  1. Clinical symptomatic brain metastasis is defined as untreated and symptomatic, or requiring steroid or anticonvulsant treatment to control related symptoms. Patients with asymptomatic brain metastasis, or with stable clinical symptoms and no need for steroid hormone and other treatments for brain metastasis for ≥28 days, can be enrolled.
  2. Have previously been treated with: another antibody-drug conjugate (ADC) consisting of DM1 or its derivative,pyrotinib and capecitabine,except for the following situations:
  3. During (neo)adjuvant therapy, received pyrotinib, and the participants who have experienced recurrence or metastasis more than 6 months after the last treatment and have not received pirlotinib since then are allowed to be enrolled;
  4. Participants who have received pirlotinib treatment during the recurrent and metastatic stage, discontinued the medication due to reasons other than disease progression, and have progressed more than 6 months after discontinuation are allowed to be enrolled;
  5. Participants who have received treatment with ADC drugs with different small molecule toxins (such as DS-8201, GQ1005, SHR-A1811, etc.) are eligible for enrollment. Such patients are also allowed to have received pirlotinib treatment during the recurrent or metastatic stage, and those who have progressed after more than 6 months of pirlotinib treatment are also eligible for enrollment.
  6. Have other malignant tumors within 5 years before signing the informed consent form ( except for cured skin basal cell carcinoma and cervical carcinoma in situ).
  7. Have a medical history of myocardial infarction or clinically significant heart diseases, including but not limited to,
  8. symptomatic congestive heart failure (CHF) (NYHA classes II-IV), or serious cardiac arrhythmia which required to therapy;
  9. Having a history of myocardial infarction or unstable angina pectoris within 6 months prior to the initial treatment,
  10. Have a corrected QT interval (QTc) prolongation to > 450 milliseconds (ms) in males and > 470 ms in females.
  11. Have clinically significant acute and chronic pulmonary diseases (e.g. interstitial lung disease (ILD), lung infection, pulmonary fibrosis, and severe radiation pneumonitis), participants with a history of ILD/non-infectious pneumonia requiring hormone therapy, or suspected of having lung diseases based on imaging examination at screening, with imaging suggesting miliary disseminated metastasis, subjects with specific pulmonary complications including but not limited to any potential lung diseases (such as pulmonary embolism, severe asthma, severe chronic obstructive pulmonary disease, restrictive lung disease, or other conditions that may interfere with the detection or management of drug-related pulmonary toxicity within 3 months prior to enrollment in the study), or subjects requiring oxygen therapy.
  12. History of allergic reaction to any component of GQ1001.
  13. The toxicity of previous anti-cancer therapy has not recovered to ≤1 as specified in CTCAE v5.0 (except for hair loss); e.g. chronic grade 2 toxicity might be determined per the investigator's judgment.
  14. The cumulative dose of anthracyclines or equivalent>500 mg/m2.
  15. Uncontrollable infections require intravenous antibiotics, antiviral drugs, or antifungal drugs.
  16. Hepatitis B virus (HBV) infection (including hepatitis B surface antigen [HBsAg] positive or hepatitis B core antibody [HBcAb] positive and HBV DNA positive); HIV, syphilis, hepatitis C antibody positive, or other severe and fatal viral or bacterial diseases, except for patients with stable hepatitis B (HBV viral copy number below the upper limit of reference value) after drug treatment and cured hepatitis C patients (HCV viral copy number below the detection limit of assay method).
  17. Per the investigator's judgment, participants with any history or current evidence of concomitant disease treatment or laboratory abnormalities may interfere with the trial results, as well as their participation and compliance.
  18. Lactating women or women who have confirmed pregnancy through a pregnancy test within 7 days prior to their first treatment.
  19. Male or female subjects unwilling to use approved contraceptive methods (e.g. birth control pills, barrier device, intrauterine device, abstinence) during the study and for 7 months following the last dose of the study drug infusion.
  20. Other circumstances that are deemed not appropriate for the study.
  21. Inability to swallow, chronic diarrhea and intestinal obstruction, or other factors that affect drug administration and absorption.

引自 ClinicalTrials.gov, NCT05575804, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT05575804,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT05575804